Tislelizumab-chemo a suitable first-line treatment alternative for advanced sq-NSCLC?
23 Aug 2021
byAudrey Abella
The addition of the monoclonal antibody tislelizumab to chemotherapy (CT) offers superior clinical benefit over CT alone as reflected by the prolonged progression-free survival (PFS), higher objective response rate (ORR), and a manageable safety and tolerability profile, underlining the potential of the combo regimen as a first-line treatment alternative for individuals with advanced squamous non-small-cell lung cancer (sq-NSCLC), the RATIONALE 307 trial suggests.
